An observational study in Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, sponsored by iOMEDICO AG. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by iOMEDICO AG · Observational
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.
JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of HCC or CCC in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.
3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 953 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 752 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →iOMEDICO AG is the lead sponsor of 52 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCC) starting treatment for early, intermediate or advanced disease
Signed and dated informed consent (IC):
Exclusion criteria:
Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)
Patients with Hepatocellular Carcinoma (HCC)
Other: Physician's choice according to patient's needs.
Patients with Cholangiocarcinoma (CCC)
Other: Physician's choice according to patient's needs.
Routine care as per site standard.
Course of treatment (treatment reality).
Documentation of anamnestic data and therapy sequences.
Time frame: 3 years per patient.
Best Response.
Documentation of response rates per line of treatment.
Time frame: 3 years per patient.
Progression-free survival.
Documentation of progression-free survival per line of treatment.
Time frame: 3 years per patient.
Overall survival.
Documentation of overall survival per line of treatment.
Time frame: 3 years per patient.
Health-related quality of life (Patient-reported outcome, PRO).
EORTC QLQ-C30 core questionnaire \[European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems\]
Time frame: 3 years per patient.
Carcinoma Health-related quality of life (Patient-reported outcome, PRO).
EORTC QLQ-HCC18, the hepatocellular carcinoma specific module / EORTC QLQ-BIL21, the cholangiocarcinoma specific module \[European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems\].
Time frame: 3 years per patient.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iOMEDICO AG